|Day Low/High||4.20 / 4.44|
|52 Wk Low/High||4.23 / 16.25|
AXIM Received Guidance and Approval on Its MedChew Rx Clinical Development Program from Dutch Authorities, Achieving Another Major Milestone for the Company's European Market Expansion
AXIM to Proceed with IND Filing of Dronabinol-Based Chewing Gum to Help Treat Chemotherapy-Related Nausea and Vomiting in Cancer and Loss of Appetite and Cachexia in HIV/AIDS Patients
Participants of AXIM Biotech's Phase IIa trial experienced a decrease in their pain score and improvement in their quality of life score, highlighting the efficacy of AXIM's patented CBD chewing gum delivery method, allowing for AXIM to move forward with further trials with predetermined dosing
New Patent Granted to AXIM Allows Use of Cannabinoid-Based Ophthalmic Solutions to Treat Glaucoma and Conjunctival Inflammation
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.